Last $53.42 USD
Change Today -0.18 / -0.34%
Volume 1.1M
As of 12:07 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$53.72
Previous Close
$53.60
Day High
$54.15
Day Low
$53.01
52 Week High
07/24/14 - $55.70
52 Week Low
11/5/13 - $36.26
Market Cap
45.6B
Average Volume 10 Days
4.3M
EPS TTM
--
Shares Outstanding
854.0M
EX-Date
08/19/14
P/E TM
--
Dividend
$1.37
Dividend Yield
2.53%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVA) Key Developments

Medpro Pharmaceutica (Pty) Ltd Enters into a Collaboration with Teva Pharmaceuticals (Pty) Ltd

Medpro Pharmaceutica (Pty) Ltd. announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd. The collaboration is restricted to the territory of South Africa. The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. The collaboration is a sales and distribution arrangement whereby Cipla Medpro will exclusively market Teva's broad pharmaceutical product portfolio in South Africa. This collaboration is highly complementary and aligns strongly with philosophy of providing South Africans with access to a broader range of affordable medicines.

Teva Pharmaceutical Industries Ltd. Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets

Teva Pharmaceutical Industries Ltd. announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release (ER) hydrocodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Teva also announced positive results from a nasal Human Abuse Liability (HAL) study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release (IR) hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. In the intranasal HAL study, abuse potential was significantly lower for crushed intranasal CEP-33237 (45 mg) than for intranasal IR hydrocodone powder (45 mg) based on peak at-the-moment drug liking and peak overall drug liking (P=0.004 for both measures). In the oral HAL study, abuse potential was significantly lower for crushed CEP-33237 (45 mg) powder than for IR hydrocodone (45 mg) based on peak at-the-moment drug liking (P<0.001). Overall drug liking was also significantly lower for crushed CEP-33237 compared to IR hydrocodone. In both studies, intact CEP-33237 showed similar abuse potential to placebo.

Teva Pharmaceutical To Divest 14 Pipeline Projects

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has completed its strategic review and has identified 14 pipeline projects for discontinuation or divestment. Teva Pharmaceutical will discuss this decision following its strategic review as well as other financial information as part of its third-quarter earnings presentation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $53.40 USD -0.20

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.34 USD -0.09
AbbVie Inc $60.00 USD +0.48
Baxter International Inc $69.74 USD +0.64
Covidien PLC $89.20 USD +0.75
Eli Lilly & Co $65.83 USD +1.48
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 17.5x
Price/Sales 2.2x
Price/Book 1.9x
Price/Cash Flow 19.6x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.